Article abstract-The Neuropsychiatric Inventory (NPI) was developed to assess psychopathology in dementia patients. It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The severity and frequency of each neuropsychiatric symptom are rated on the basis of scripted questions administered to the patient's caregiver. The NPI also assesses the amount of caregiver distress engendered by each of the neuropsychiatric disorders. A total NPI score and a total caregiver distress score are calculated, in addition to the scores for the individual symptom domains. Content validity, concurrent validity, inter-rater reliability, and testretest reliability of the NPI are established. Different neurologic disorders have characteristic neuropsychiatric manifestations and distinctive NPI profiles. The NPI is sensitive to treatment effects and has demonstrated the amelioration of behavioral symptoms in Alzheimer's disease by cholinergic agents. The NPI is a useful instrument for characterizing the psychopathology of dementia syndromes, investigating the neurobiology of brain disorders with neuropsychiatric manifestations, distinguishing among different dementia syndromes, and assessing the efficacy of treatment. NEUROLOGY 1997;48(Supp16): Neuropsychiatric disturbances are a major manifestation of Alzheimer's disease (AD) and other dementing illnesses, with important consequences for patients and ~aregivers.l-~ Demented patients with delusions, for example, engage in more physical aggression than those without delusions; and aggressive patients are more likely to be abused by caregive r~.~,~ Delusional patients are also noisier, more restless, and more prone to wander than nondelusional patient^.^ Dementia patients with delusions and other behavioral disturbances are more likely to be admitted to nursing homes than nondelusional dementia patients with equally severe cognitive changes.*-ll Once admitted to a nursing home, agitated patients require more staff supervision than patients without agitation. [12][13][14] In one study, physical violence, catastrophic reactions, delusions, and accusatory behavior were considered a problem for more than 80% of families reporting the occurrence of these beha~i0rs.l~ Caregiver perception of patient depression is a predictor of caregiver burden, whereas perceptions of patient memory, self-care, and language are not.16 These observations emphasize the relative importance of neuropsychiatric disorders compared with cognitive changes for caregiver distress. Neuropsychiatric abnormalities are associated with higher patient care costs related to greater medication use, earlier nursing home admission, and higher staffing requirements in institutions.
Neuropsychiatric disturbances are a major manifestation of Alzheimer's disease (AD) and other dementing illnesses, with important consequences for patients and ~aregivers.l-~ Demented patients with delusions, for example, engage in more physical aggression than those without delusions; and aggressive patients are more likely to be abused by caregive r~.~,~ Delusional patients are also noisier, more restless, and more prone to wander than nondelusional patient^.^ Dementia patients with delusions and other behavioral disturbances are more likely to be admitted to nursing homes than nondelusional dementia patients with equally severe cognitive changes.*-ll Once admitted to a nursing home, agitated patients require more staff supervision than patients without agitation. [12] [13] [14] In one study, physical violence, catastrophic reactions, delusions, and accusatory behavior were considered a problem for more than 80% of families reporting the occurrence of these beha~i0rs.l~ Caregiver perception of patient depression is a predictor of caregiver burden, whereas perceptions of patient memory, self-care, and language are not.16 These observations emphasize the relative importance of neuropsychiatric disorders compared with cognitive changes for caregiver distress. Neuropsychiatric abnormalities are associated with higher patient care costs related to greater medication use, earlier nursing home admission, and higher staffing requirements in institutions.
The importance of neuropsychiatric disturbances in dementias requires that they be assessed in the course of clinical care and quantified for research purposes. This article presents results of studies with the Neuropsychiatric Inventory (NPI),17 an instrument developed to assess psychopathology in dementia patients.
i~r .~~J~ After completion of the original scale, two additional items-night-time behavior disturbances and changes in appetite and eating behaviors-were added to expand the number of neuropsychiatric syndromes assessed and to provide a more complete evaluation of behavioral changes common in dementia patients.
Several of the NPI subscales require comment. The dysphoria subscale assesses depressed mood. Evaluating depression in demented patients is challenging because symptoms of the two syndromes overlap. Weight loss, appetite changes, sleep disturbances, agitation, retardation, delusions, obsessions, and cognitive abnormalities are characteristic of both dementia and depre~si0n.l~ Rating scales with these items may have elevated scores produced by either syndrome or a coexistence of both. To ensure that an elevated "depression" scale score pertains to mood changes per se, the scale must use items that differentiate depression from dementia. Therefore, the questions and subquestions in the dysphoria subscale of the NPI assess the core psychological and behavioral manifestations of depression, including tearfulness, sadness, statements reflecting thoughts of worthlessness and hopelessness, verbalizations regarding feelings of helplessness, and statements about death and suicide.
Neurovegetative abnormalities affecting sleep, appetite, and libido are not assessed as part of the dysphoria subscale. Sleep and appetite disturbances are common in dementia and depression. The addition of these two items as separate subscales of the NPI enables the neurovegetative aspects of dementia or depression to be characterized. A classic depression syndrome would produce elevations in the dysphoria, sleep, and appetite subscales, with or without elevations in the apathy, anxiety, and aberrant motor behavior subscales. A typical AD type of dementia without mood changes might have elevations of sleep, appetite, aberrant motor behavior, apathy, and irritability subscales without any changes recorded in the dysphoria subscale.
Many scales now used in dementia research do not include alterations in personality, such as apathy and irritability. However, recent studies suggest that these are among the most common behavioral changes that occur in dementia patients.20-22 Moreover, they are distressing to caregivers and may be important targets for therapy (reference 23; and Kaufer et al., personal communication) . The NPI includes these items to encompass common behaviors in dementias.
Most dementia rating scales were constructed to assess the behavioral symptoms of AD. The NPI helps to distinguish among different dementias and includes symptoms known to be rare in AD but common in other types of dementia. For example, euphoria and disinhibition are uncommon in AD but are characteristic of frontotemporal d e m e n t i a~.~~-~~ These two features are included in the NPI to increase its differential diagnostic utility.
Aberrant motor behavior refers to the spontaneous activities engaged in by many dementia patients. Included are the purposeless activities common in AD patients, such as pacing and r~m r n a g i n g ,~~ as well as behaviors more common in frontotemporal dementias, including compulsions and repetitive stereotyped behaviors.28
Whenever possible, terminology used in the subquestions was derived from standardized diagnostic criteria such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition.29 Administration. To minimize administration time, screening questions were developed to provide an overview of each specific behavioral domain. Caregivers familiar with the patient's behavior are interviewed using scripted questions. The caregiver is asked if the patient's behavior has changed since the onset of the dementia and if the altered behavior has been present during the past month. Other time intervals can be used depending on the circumstances. If the tool is used in a treatment study, for example, the interval might be adjusted to the time of last dosage change. The screening questions have been shown to have a false-negative rate (failure to detect psychopathology that is revealed if all of the subquestions are asked) of less than 5%.17 If the caregiver indicates that the abnormal behaviors were present in the specified time interval, the behavioral domain is then explored with seven or eight subquestions that provide more detailed information about the neuropsychiatric disturbance. After the subquestions are answered, the caregiver is asked to rate the frequency of the symptoms of that domain on a scale of 1 to 4 (1 = occasionally, less than once per week; 4 = very frequently, once or more per day or continuously) as well as their severity (1 = mild, 2 = moderate, 3 = severe). The questions are read aloud by the examiner; defined anchor points for severity and frequency maintain the reliability of caregiver responses.
Caregiver distress is rated by the caregiver on a six-point scale from 0 (no distress) to 5 (very severe or extreme distress), as described by Kaufer et al. (personal communication) .
After the subquestions are asked, each domain is rated for frequency, severity, and degree of caregiver distress produced. The total score for each domain is calculated by multiplying the frequency by the severity. A total score is calculated by adding all the domain scores together. There is a caregiver distress score for each neuropsychiatric domain found to be abnormal and a total distress score consisting of the sum of the individual scores.
Having separate scores for severity and frequency for each domain potentially increases the utility of the NPI in drug efficacy studies because effects on frequency (events occur less frequently but each event has not changed in severity) versus effects on severity (events occur just as often after treatment but are of diminished intensity) can be dissociated.
Scoring.
Psychometric properties of the NPI. Validity. Content validity. For behaviors such as apathy, irritability, disinhibition, and euphoria, there was no "gold standard instrument to which the NPI could be compared. Therefore, a group of experts was asked to participate in a "Delphi" panel and instructed to rate the scale items. The NPI was submitted to 10 nationally and internationally known experts in geriatric psychiatry, behavioral neurology, or neuropsychology (panel members are listed in Acknowledgments). Each panel member rated both the screening questions and the subquestions of each behavioral domain. Screening questions and subquestions were rated between 1 (well assessed) and 4 (poorly assessed); criteria for scoring were provided. Each group of questions, except those assessing a category labeled "troublesome behavior," received scores of less than 2, indicating high content validity. "Troublesome behavior" was reformulated as the current "aberrant motor behavior" category in accordance with the Delphi panel's recommendations.
Concurrent validity was determined by comparing the scores on the relevant subtests of the NPI with the BEHAVE-ADZ7 and Hamilton Rating Scale for Depression (HAM-D).30 The NPI subscales for delusions, hallucinations, dysphoria, anxiety, aggression, and aberrant motor behavior were compared with the BEHAVE-AD subscales for delusions, hallucinations, affective disturbances, anxiety and phobias, aggressiveness, and activity disturbances. The dysphoria subscale of the NPI was compared with the depression score of the HAM-D.
Forty subjects and 40 caregivers participated in the concurrent validity study.17 The patients included 22 men and 18 women, aged 56 to 90 (mean 75.7). All patients were assessed with the MiniMental State Examination (MMSE)31 and had scores ranging from 0 to 29 (mean 19.2). Twenty patients had AD, nine had vascular dementia, and 11 had other types of dementing disorders. Patients exhibited a wide array of neuropsychiatric abnormalities.
All correlations reached the 0.05 level of significance and all but one reached the 0.01 significance level, indicating that the NPI is not significantly different from the BEHAVE-AD or the HAM-D in its quantification of behavioral symptoms. This analysis demonstrates an acceptable level of concurrent validity compared with standard instruments.
Reliability. Between-rater reliability. Betweenrater reliability was determined by having two raters score the NPI responses of an interview conducted by one of the raters. Each rater was blind to the rating chosen by the other. The 45 patient evaluations in the between-rater reliability study included 26 men and 19 women with MMSE scores ranging from 1 to 29 (mean 17.4).17 Analysis demonstrated that the NPI is highly reliable when used by different examiners. Between-rater reliability varied from 93.6 to 100% for different behaviors.
Test-retest reliability. NPI profiles of normal elderly. To determine the NPI profile of normal elderly, 40 spouses of nondemented control subjects were interviewed. All subjects about whom information was obtained in this study had MMSE scores of 25 or above (mean 28.4) to establish the absence of major cognitive abnormalities. As with patient caregivers, interviewees were asked about behaviors that differed from the partner's usual behavior and had occurred within the past 4 weeks.17
The maximal possible score (frequency X severity) of any subscale is twelve. In the normal control sample, all NPI scores were zero except for dysphoria, disinhibition, and irritability. Mean depression score (severity X frequency) was 0.25 (range 0 to 6), mean disinhibition score was 0.13 (range 0 to 4), and mean irritability score was 0.05 (range 0 to 2). Spouses of normal control subjects did not observe delusions, hallucinations, agitation, anxiety, euphoria, apathy, or aberrant motor behaviors in their partners. Therefore, the NPI is little influenced by normal aging; only a few categories have scored responses, and the mean scores of domains with alterations are low. Conversely, elevation of NPI scale scores should be regarded as important evidence for the presence of psychopathology.
NPI profile of AD. Fifty subjects with AD, including 24 women, were assessed with the NPI.18 Mean age was 75 and mean MMSE was 16.2. Eighty-eight percent of patients exhibited neuropsychiatric changes detectable by the NPI. Only 12% of subjects had no evidence of psychopathology. Apathy was the most common neuropsychiatric abnormality recorded (72%), followed by agitation (60%), anxiety (48%), irritability (42%), dysphoria and aberrant motor behavior (38% each), disinhibition (36%), delusions (22%), hallucinations (lo%), and euphoria (8%).
No relationship was observed between age and psychopathology; one domain, agitation, exhibited a significant gender difference and was more common in men. Five neuropsychiatric abnormalities increased with dementia severity: agitation, dysphoria, anxiety, apathy, and aberrant motor behavior. Disinhibition decreased with dementia severity. Table 1 shows the percentages of patients in different stages of AD with neuropsychiatric symptoms. 
Differential diagnostic properties of the NPI.
One goal of the NPI is to establish characteristic neuropsychiatric profiles of different neurologic disorders. A variety of conditions have been studied, including AD,18 frontotemporal d e m e n t i a~,~~ and progressive supranuclear palsy.32 Significant differences on NPI profiles emerged. Patients with frontotemporal dementias exhibited significantly more apathy, disinhibition, euphoria, and aberrant motor behavior than those with AD. Patients with progressive supranuclear palsy had significantly more apathy and less agitation and anxiety than AD. Study of the NPI profiles of other neurologic disorders is warranted. Establishing behavior profiles that characterize different disorders may help to reduce diagnostic error when patients are recruited to participate in clinical trials. Studying the relationship between disease-specific profiles and pathologic changes will enhance our understanding of the neurobiological changes that produce the neuropsychiatric abnormalities.
Biological correlates of the NPI. Investigation of the relationship between apathy, the most common behavioral change occurring in AD, and regional cerebral blood flow, measured by single photon emission computed tomography (SPECT), revealed that changes in prefrontal and anterior temporal perfusion are most highly correlated with NPI apathy scores.33 Study of the regional metabolic and perfusion correlates of the NPI demonstrates that neuropsychiatric abnormalities reflect regional brain dysfunction.
"PI scores and caregiver distress. Neuropsychiatric disorders contribute significantly to caregiver the NPI quantifies the distress associated with each type of abnormality exhibited by the patient. Total NPI scores are significantly associated with total caregiver distress scores, and individual behaviors contribute variably to the amount of distress experienced by the caregiver (Kaufer et al., personal communication) . The association of individual patient behaviors with various levels of caregiver distress has treatment implications. If individual behaviors respond to treatment, then there is a potential to reduce the associated distress.
Transnational studies with the NPI. Comparison of neuropsychiatric symptoms in different cultures can provide insight into the relative contributions of biology and culture to behavioral changes. A recent report compared NPI scores of AD patients from the United States, Italy, and
In all groups, apathy and anxiety were the most common symptoms (among the top three items in all nations); disinhibition, hallucinations, and euphoria were rare (among the bottom four items in all nations). The similarities across cultures indicate that some neuropsychiatric abnormalities are more biologically and less culturally determined.
NPI scores as a measure of treatment response.
The NPI has been used to assess changes in neuropsychiatric symptoms after treatment with tacrine, a cholinesterase inhibitor. In an open-label of tacrine therapy in 28 AD patients (mean MMSE score 14.9), there was a dose-related reduction in total NPI scores. Among the subscales, there was significant improvement in disinhibition and anxiety and near-significant changes in apathy and aberrant motor behavior. Hallucinations also improved, but the total number of patients with hallucinations before treatment was small. Patients with MMSE scores between 10 and 20 exhibited the most robust improvement in neuropsychiatric symptoms.
This study suggested that the NPI provides valuable insight into the magnitude and characteristics of patients' responses to medications. By fractionating the response into individual behavioral domains, the NPI reveals which neuropsychiatric symptoms respond best to treatment. In addition, these findings suggest that cholinergic therapy may have substantial behavioral benefit and that the NPI is sensitive to changes in neuropsychiatric symptoms induced by cholinomimetic agents. The NPI also may aid in documenting the amelioration of neuropsychiatric disturbances produced by conventional psychotropic agents.
Comment. Neuropsychiatric disturbances are primary manifestations of brain dysfunction in AD and other dementias. This position is supported by studies of the natural history, associated neuroimaging abnormalities, related cognitive disturbances, neuropathologic correlates, and treatment responses of the neuropsychiatric aspects of AD, the most well-investigated of the dementias. Natural history and neuroimaging studies reveal that patients with delusions have more rapid cognitive decline and more marked abnormalities of metabolism and perfusion in the frontal and temporal lobes than patients without delusion^.^^-^^ EEG changes are also more marked in AD patients with delusions. 48 The lack of consistent relationships between cognitive and neuropsychiatric abnormalities provides evidence that neuropsychiatric abnormalities are not reactive to cognitive impairment. AD patients with delusions tend to have more changes in language and executive function than nondelusional patients, but the cognitive differences are not ~a r k e d .~~-~l Moreover, delusions and hallucinations have occasionally been the presenting symptom of AD, antedating any cognitive a b n o r m a l i t i e~.~~.~~ Investigations of the relationship between depression and insight into one's cognitive decline also fail to reveal marked associations. Mood changes were similar in patients who rated their memory as severely abnormal compared with those who rated their memory as intact (both groups had severely impaired memory).19
Neuropathologic and neurochemical studies support a relationship between neuropsychiatric disorders in AD and the underlying neurobiology of the d i~o r d e r .~~-~~ Psychosis in AD has been associated with significantly increased densities of senile plaques in the prosubiculum and of neurofibrillary tangles in the middle frontal cortex.57 There were also higher norepinephrine levels in the substantia nigra and lower serotonin levels in the prosubiculum of psychotic compared with nonpsychotic AD pat i e n t~.~~ Similarly, aggressive patients have better preservation of the substantia nigra than nonaggressive AD patients studied at Depression in AD has been related to the severity of alterations in the locus ceruleus, substantia nigra, and dorsal raphe n u~l e i .~~,~O Finally, the response of behavioral symptoms in AD to cholinergic treatment suggests that the cholinergic deficiency of AD, a defining neurobiological feature, contributes importantly to the neuropsychiatric manifestations of the d i~e a s e .~~,~~ Together, these observations indicate that the neuropsychiatric aspects of dementia are primary manifestations of the underlying neurobiological changes.
The neuropsychiatric abnormalities of dementias are sometimes regarded as secondary symptoms because, unlike cognitive disturbances, they are not present in all patients and do not necessarily progress with other aspects of the illness. The neuropsychiatric alterations of dementia are comparable with symptoms such as ophthalmoplegia in multiple sclerosis, i.e., their occurrence in all patients and progression in concert with other aspects of the disease are not needed to establish them as manifestations of brain dysfunction. The presence of such symptoms is determined by the areas of the brain affected at different times in the course of the illness. Individual variability in dementing diseases such as AD leads to subtypes with and without neuropsychi- The neurobiological basis of these symptoms may include neurochemical changes and interactions between transmitters that are dynamic and change over time, accounting for the temporal inconstancy of the symptoms. Lack of occurrence in all patients and lack of steady progression in the course of the illness do not indicate that the neuropsychiatric manifestations are secondary or optional. They suggest that patients with neuropsychiatric abnormalities comprise a subgroup with distinctive neurobiological characteristics.
Identification of neuropsychiatric disturbances as primary manifestations of dementia makes it imperative that instruments are available for their accurate detection and quantification. The NPI was designed to assess psychopathology in dementia. It is psychometrically sound, comprehensive, and sensitive to change. It was constructed specifically for use with dementia patients and includes the most common and the most troublesome behaviors encountered in dementia syndromes. The NPI is particularly valuable in the clinical trial setting. Drugs used to treat AD and other dementias have both neuropsychiatric and cognitive effects, and assessment of the neuropsychiatric impact of administered agents should be a standard part of all clinical trial protocols. The features that characterize the NPI are listed in table 2.
In summary, neuropsychiatric abnormalities are primary manifestations of brain dysfunction in dementia patients. They are common and have important consequences for patients and caregivers. Assessment of the psychopathologic dimension of dementia is imperative in clinical care and research, and the NPI has promise as a useful instrument for this purpose.
